Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.…
Evogene (EVGN) Q3 2026 Earnings Call Transcript
Evogene (NASDAQ: EVGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 38 employees.
The shares were at 0.3162 USD on 20 November 2026, down 74.7% over 52 weeks. Its 52-week range is 0.2503 USD to 1.260 USD: the price is 74.9% below the high and 26.3% above the low.
Its market capitalisation is 5.71M USD.
Evogene reports revenue down 60.7% year over year.
It holds more cash than debt, a net cash position of 7.21M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 4 March 2027.